CPA
FHTX icon

Capital Performance Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Capital Performance Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14
Closed -$130 – 1039
2024
Q3 		$130 Buy
+14
New +$101 ﹤0.01% 2650

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's FHTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Foghorn Therapeutics (FHTX) in Q4 2024, closing a stake of 14 shares — an estimated $130 sold.

Capital Performance Advisors first reported a position in FHTX in Q3 2024 and held it in 1 quarter. The position peaked at $130 in Q3 2024. 87 funds tracked by Wall St. Rank hold FHTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Foghorn Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 14 Foghorn Therapeutics shares in Q4 2024, an estimated $130.
  • Capital Performance Advisors first reported a position in Foghorn Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Foghorn Therapeutics position peaked at $130 in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.